[Value of convalescent plasma in the therapy of COVID-19].

Convalescent plasma was discussed as a therapeutic option early in the course of the COVID-19 pandemic. However, until the onset of the pandemic, only the results of mostly small single-arm studies in other infectious diseases were available, which did not prove efficacy. In the meantime, the results of more than 30 randomized trials of COVID-19 convalescent plasma (CCP) for treatment of COVID-19 are available 1. Despite the heterogeneity of the results, conclusions for an optimal use are possible.
Competing Interests: Prof. Dr. Hubert Schrezenmeier, Prof. Dr. Dr. h.c. Erhard Seifried und Dr. Sixten Körper haben durch das BMG und BMBF geförderte klinische Prüfungen zum Einsatz von Rekonvalesztenplasma durchgeführt und sind bei Institutionen tätig, die Plasmapräparate herstellen.
(Thieme. All rights reserved.)